Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.65 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1925893 | 0.81 | SMN1; SMN2 (0.77) | SMN1; SMN2ALOX15NAAAL3MBTL1DRD2 | |
| SCHEMBL16117373 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53BP1NAAAL3MBTL1 | |
| SCHEMBL4557886 | 0.77 | HTR1A (0.64) | CAMK2DNAAA | |
| SCHEMBL18644975 | 0.76 | NR5A2 (0.61) | CAMK2DALOX15 | |
| SCHEMBL10242958 | 0.75 | SMN1; SMN2 (0.67) | SMN1; SMN2CAMK2DKAT6AALOX15NAAA | |
| SCHEMBL161905 | 0.75 | SMN1; SMN2 (0.81) | SMN1; SMN2TP53BP1NAAAL3MBTL1DRD2 | |
| SCHEMBL13693382 | 0.75 | SMN1; SMN2 (0.87) | SMN1; SMN2TP53BP1NAAAL3MBTL1 | |
| SCHEMBL842634 | 0.75 | SMN1; SMN2 (0.81) | SMN1; SMN2NAAAL3MBTL1 | |
| SCHEMBL161904 | 0.75 | SMN1; SMN2 (0.81) | SMN1; SMN2TP53BP1NAAAL3MBTL1 | |
| SCHEMBL31055438 | 0.75 | L3MBTL1 (0.82) | SMN1; SMN2TP53BP1NAAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | SMN1; SMN2 3120/4885CAMK2D 4642/4885KAT6A 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.